PT  - JOURNAL ARTICLE
AU  - Patel, Chirag J.
AU  - Ioannidis, John PA
AU  - Gregg, Edward W.
AU  - Vasan, Ramachandran S.
AU  - Manrai, Arjun K.
TI  - Heterogeneity in elevated glucose and A1C as predictors of the prediabetes to diabetes transition: Framingham Heart Study, Multi-Ethnic Study on Atherosclerosis, Jackson Heart Study, and Atherosclerosis Risk In Communities
AID  - 10.1101/2024.03.16.24304398
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.16.24304398
4099  - http://medrxiv.org/content/early/2024/03/18/2024.03.16.24304398.short
4100  - http://medrxiv.org/content/early/2024/03/18/2024.03.16.24304398.full
AB  - Aims/hypothesis There are a number of glycemic definitions for prediabetes; however, the heterogeneity in diabetes transition rates from prediabetes across different glycemic definitions in major US cohorts has been unexplored. We hypothesize that a significant source of variation in the transition rate are cohorts themselves. We estimate the variability in risk and relative risk of diabetes based on diagnostic criteria like fasting glucose and hemoglobin A1C% (HbA1c%).Methods We estimated transition rate from prediabetes, as defined by fasting glucose between 100-125 and/or 110-125 mg/dL, and HbA1c% between 5.7-6.5% in participant data from the Framingham Heart Study (FHS) Generation 2, FHS Generation 3, Multi-Ethnic Study on Atherosclerosis, Atherosclerosis Risk in Communities, and the Jackson Heart Study. We estimated the heterogeneity and prediction interval across cohorts, stratifying by age, sex, and body mass index. Among individuals with prediabetes, we estimated the relative risk for obesity, blood pressure, education, age, and sex for diabetes.Results There is substantial heterogeneity in diabetes transition rates across cohorts and prediabetes definitions with large prediction intervals. We observed the individuals with fasting glucose of 100-125 range from 4-14% per 100 person years and 110-125 mg/dL ranging from 2-18 per 100 person-years. For HbA1C between 5.7-6.5%, the transition rate ranged from 2.5-11 per 100 person years (I2 for heterogeneity was greater than 93% for all definitions). Obesity and hypertension did not explain the differences in risk.Conclusion The absolute transition rate from prediabetes to diabetes significantly depends on both cohort and prediabetes definitions.Research in context What is already known about this subject? The prevalence of prediabetes and the transition rate to diabetes vary significantly across different populations and are influenced by the diagnostic criteria used, such as fasting glucose levels and HbA1C percentages.Definitions of prediabetes by organizations like the American Diabetes Association (ADA) and World Health Organization (WHO) influence the estimation of diabetes transition risk.Previous studies have shown a wide range of diabetes transition rates from prediabetes, implying potential heterogeneity in risk assessments across different cohorts. What is the key question? How does the heterogeneity in diabetes transition rates from prediabetes across different glycemic definitions affect our understanding and management of the risk in major US cohorts? What are the new findings? There is substantial heterogeneity in diabetes transition rates across different US cohorts and prediabetes definitions, with large prediction intervals.Obesity and hypertension do not account for the differences in transition risk, suggesting other between cohort factors are at play. How might this impact clinical practice in the foreseeable future? Understanding the variability in diabetes transition rates across different populations and definitions is important for planning for precision medicine approaches in diabetes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by NIEHS R01ES032470 and the funder had no role in the design and reporting of the study. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Harvard University gave ethnical approval for this work (IRB21-1596).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available from the NHLBI BioLINCC repository.